Compare
McCormick & Co Inc vs Utz Brands, Inc. vs Medifast Inc
| Latest fiscal year | McCormick & Co Inc MKC | Utz Brands, Inc. UTZ | Medifast Inc MED |
|---|---|---|---|
| Year ended | 2025-11-30 | 2025-12-28 | 2025-12-31 |
| Revenue | $6.84B | $1.44B | $385.79M |
| Revenue growth (YoY) | +1.7% | +2.1% | -36.0% |
| Gross margin | 37.9% | 24.9% | 71.3% |
| Operating margin | 15.7% | 1.4% | -3.7% |
| Net margin | 11.5% | 0.1% | -4.8% |
| Net income | $789.40M | $800.0K | -$18.67M |
| EPS (Diluted) | $2.93 | $0.01 | -$1.70 |
| Operating cash flow | $962.20M | $112.20M | $6.86M |
| Free cash flow | $740.40M | $9.40M | $1.25M |
| Cash & equivalents | $95.90M | $120.40M | $89.30M |
| Total assets | $13.20B | $2.79B | $247.97M |
| Total liabilities | $7.43B | $1.45B | $49.05M |
| Shareholders' equity | $5.77B | $713.70M | $198.92M |
| Return on year-end equity | 13.7% | 0.1% | -9.4% |
| Shares outstanding | n/a | n/a | 10.99M |
Revenue, most recent five fiscal years
| Fiscal year | McCormick & Co Inc | Utz Brands, Inc. | Medifast Inc |
|---|---|---|---|
| Latest | $6.84B Ended 2025-11-30 | $1.44B Ended 2025-12-28 | $385.79M Ended 2025-12-31 |
| 1 year earlier | $6.72B Ended 2024-11-30 | $1.41B Ended 2024-12-29 | $602.46M Ended 2024-12-31 |
| 2 years earlier | $6.66B Ended 2023-11-30 | $1.44B Ended 2023-12-31 | $1.07B Ended 2023-12-31 |
| 3 years earlier | $6.35B Ended 2022-11-30 | $1.41B Ended 2023-01-01 | $1.60B Ended 2022-12-31 |
| 4 years earlier | $6.32B Ended 2021-11-30 | $1.18B Ended 2022-01-02 | $1.53B Ended 2021-12-31 |